Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tirzepatide Devices in Healthy Participants
NCT05810597Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration, Area Under the Plasma Concentration Versus Time Curve From Zero to Time t and 1 more. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05810597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810597.